Methods of treatment using CTLA4 mutant molecules

Details Methods of treatment using CTLA4 mutant molecules Methods of treatment using CTLA4 mutant molecules

2004-11-03

2008-10-21

Ouspenski, Ilia (Department: 1644)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C424S134100, C530S350000, C530S387300

Reexamination Certificate

active

07439230

ABSTRACT:
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

REFERENCES:
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5521288 (1996-05-01), Brady et al.
patent: 5580756 (1996-12-01), Brady et al.
patent: 5637481 (1997-06-01), Ledbetter et al.
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5773253 (1998-06-01), Linsley et al.
patent: 5844095 (1998-12-01), Linsley et al.
patent: 5851795 (1998-12-01), Linsley et al.
patent: 5883223 (1999-03-01), Gray
patent: 5885579 (1999-03-01), Linsley et al.
patent: 5885796 (1999-03-01), Linsley et al.
patent: 5916560 (1999-06-01), Larsen et al.
patent: 5958403 (1999-09-01), Strom et al.
patent: 5968510 (1999-10-01), Linsley et al.
patent: 5977318 (1999-11-01), Linsley et al.
patent: 5993800 (1999-11-01), Linsley et al.
patent: 6090914 (2000-07-01), Linsley et al.
patent: 6132992 (2000-10-01), Ledbetter et al.
patent: 6352694 (2002-03-01), June et al.
patent: 6444792 (2002-09-01), Gray et al.
patent: 6534055 (2003-03-01), June et al.
patent: 6641809 (2003-11-01), Brady et al.
patent: 6685941 (2004-02-01), Thompson et al.
patent: 6719972 (2004-04-01), Gribben et al.
patent: 6750334 (2004-06-01), Gray et al.
patent: 6830937 (2004-12-01), Brady et al.
patent: 6887471 (2005-05-01), Linsley et al.
patent: 2001/0053361 (2001-12-01), Thompson et al.
patent: 2002/0031510 (2002-03-01), Larsen et al.
patent: 2002/0039577 (2002-04-01), Todderud et al.
patent: 2002/0115214 (2002-08-01), June et al.
patent: 2003/0007968 (2003-01-01), Larsen et al.
patent: 2003/0022836 (2003-01-01), Larsen et al.
patent: 2003/0083246 (2003-05-01), Cohen et al.
patent: 2003/0219863 (2003-11-01), Peach et al.
patent: 2004/0014171 (2004-01-01), Peach et al.
patent: 2004/0022787 (2004-02-01), Cohen et al.
patent: 2005/0019859 (2005-01-01), Schilling et al.
patent: 2005/0084933 (2005-04-01), Schilling et al.
patent: 2005/0123539 (2005-06-01), Rusnak
patent: 0 613 944 (1994-09-01), None
patent: 0 682 039 (1995-11-01), None
patent: 757099 (1997-05-01), None
patent: WO 90/05541 (1990-05-01), None
patent: WO 93/00431 (1993-01-01), None
patent: WO 93/19767 (1993-10-01), None
patent: WO 94/28912 (1994-12-01), None
patent: WO 95/01994 (1995-01-01), None
patent: WO 95/33770 (1995-12-01), None
patent: WO 95/34320 (1995-12-01), None
patent: WO 96/14865 (1996-05-01), None
patent: WO 97/34633 (1997-03-01), None
patent: WO 97/28267 (1997-08-01), None
patent: WO 97/37687 (1997-10-01), None
patent: WO 97/47732 (1997-12-01), None
patent: WO 98/31820 (1998-07-01), None
patent: WO 98/33513 (1998-08-01), None
patent: WO 98/56417 (1998-12-01), None
patent: WO 99/29883 (1999-06-01), None
patent: WO 99/47558 (1999-09-01), None
patent: WO 99/49734 (1999-10-01), None
patent: WO 99/51275 (1999-10-01), None
patent: WO 99/57266 (1999-11-01), None
patent: WO 00/23115 (2000-04-01), None
patent: WO 01/54732 (2001-08-01), None
patent: WO 01/90122 (2001-11-01), None
patent: WO 01/92337 (2001-12-01), None
patent: WO 02/02638 (2002-01-01), None
patent: WO 2004/058800 (2004-07-01), None
patent: WO 2004/058944 (2004-07-01), None
patent: WO 2005/016266 (2005-02-01), None
Blazar et al., J. Immunol., 1996, 157: 3250-3259.
Huang Z., Pharmacology and Therapeutics, 2000, 86: 201-215.
Metzler et al., Nature Structural Biol. 1997; 4:527-531.
Lakkis, Fadi G., et al., “Blocking the CD28-B7 T Cell Costimulation Pathway Induces Long Term Cardiac Allograft Acceptance in the Absence of IL-41,”The Journal of Immunology, 1997, 158:2443-2448. (Exhibit 139).
Pearson, Thomas C., et al., “Analysis of the B7 Costimulatory Pathway in Allograft Rejection1,”Transplantation, 1997, 63:1463-1469. (Exhibit 140).
Pearson, Thomas C., et al., “Transplantation Tolerance Induced by CTLA4-Ig1,”Transplantation, 1994, 57:1701-1706. (Exhibit 141).
Alexander, Diane Z., “Analysis of a Functional Role for Chimerism in CTLA4-Ig Plus Bone Marrow-Treated Cardiac Allograft Recipients,”Transplantation, 1994, 91:416-418. (Exhibit 142).
Larsen, Christian P., et al., “CD40-gp39 Interactions Play a Critical Role During Allofraft Rejection”Transplantation, 1996, 61:4-9. (Exhibit 143).
Pearson, Thomas C., et al., “CTLA4-Ig Plus Bone Marrow Induces Long-Term Allograft Survival and Donor-Specific Unresonsiveness in the Murine Model”,Transplantation, 1996, 61:997-1004. (Exhibit 144).
Weber, C.J., et al., “CTLA4-Ig Prolongs Survival of Microencapsulated Rabbit Islet Xenografts in Spontaneously Diabetic Nod Mice,”Transplantation Proceedings, 1996, 28:821-823. (Exhibit 145).
Alexander, D.Z., et al., “Analysis of effector mechanisms in murine cardiac allograft rejection,”Transplantation Immunology, 1996, 4:46-48. (Exhibit 146).
Larsen, Christian P., et al., “Long-Term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways,”Nature, 1996, 381:434-438. (Exhibit 147).
Elwood, Eric T., et al., “Microchimerism and rejection in clinical transplantation,”The Lancet, 1997, 349:1358-1360. (Exhibit 148).
Larsen, Christian P., and Thomas C. Pearson., “The CD40 pathway in allograft rejection, acceptance, and tolerance,”Transplantation, 1997,9:641-647. (Exhibit 149).
Konieczny, Bogumila T.., et al., “IFN-γ Critical for Long-Term Allograft Survival Induced by Blocking the CD28 and CD40 Ligand T Cell Constimulation Pathways1,”The Journal of Immunology, 1998,160:2059-2064. (Exhibit 150).
Elwood, Eric T., et al., “Prolonged Acceptance of Concordant and Discordant Xenografts With Combined CD40 and CD28 Pathway Blockade1,”Transplantation, 1998,65:1422-1428. (Exhibit 151).
Niimi, Masanori, et al., “The Role of the CD40 Pathway in Alloantigen-Induced Hyporesonsiveness in Vivo1,”The Journal of Immunology, 1998,161:5331-5337. (Exhibit 152).
Whitmire, Jason K., et al., “CD40-CD40 Ligand Costimulation Is Required for Generating Antiviral CD4 T Cell Responses But is Dispensable for CD8 T Cell Responses1,”The Journal of Immunology, 1999,163:3194-3201. (Exhibit 153).
Bingaman, Adam W., et al., “Vigorous Allograft Rejection in the Absence of Danger1,”Journal of Immunology, 2000,164:3065-3071. (Exhibit 154).
Bingaman, Adam W., et al., “Transplantation of the Bone Marrow Microenviroment Leads to Hematoppietic Chimerism Without Cytoreductive Conditioning,”Transplantation, 2000, 69:2491-2496. (Exhibit 155).
Durham, Megan M., et al., “Cutting Edge: Administration of Anti-CD40 Ligand and Donor Bone Marrow Leads to Hemapoietic Chimerism and Donor-Specific Tolerance Without Cytoreductive Conditioning1,”Cutting Edge, 2000,165:1-4. (Exhibit 156).
Williams, Matthew A., et al., “Genetic Characterization of Strain Differences in the Ability to Mediate CD40/CD28-Independent Rejection of Skin Allografts1,”The Journal of Immunology, 2000, 165: 6549-6857. (Exhibit 157).
Bingaman, Adam W., et al., “The role of CD40L in T cell-dependent nitric oxide production by murine macrophages,”Transplant Immunology, 2000, 8:195-202. (Exhibit 158).
Adams, Andrew B., et al., “Costimulation Blockade, Busulfan, and Bone Marrow Promote Titratable Macrochimerism, Induce Transplantation Tolerance, and Correct Genetic Hemoglobinopathies with Minimal Myelosuppression1,”The Journal of Immunology, 2001, 167:1103-1111. (Exhibit 159).
Meng, L., “Blockade of the CD40 Pathway Fails to Prevent CD8 T Cell-Mediated Intestinal Allograft Rejection,”Transplantation Proceedings, 2001, 33:418-420. (Exhibit 160).
Guo, Zhong., et al., “CD8 T Cell-Mediated Reje

Affiliated with

Also associated with

Rating

Methods of treatment using CTLA4 mutant molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treatment using CTLA4 mutant molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using CTLA4 mutant molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4010230